BioSpace News Archive

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the BofA Securities 2021 Health Care Conference at 11:45 a.m. ET on May 12, 2021.

Centene Corporation (NYSE: CNC) announced today that Drew Asher is appointed Executive Vice President and Chief Financial Officer, effective today

Pink Luminous Breast (PLB) is continuing to make strides in breast cancer awareness with a new clinical study released exploring the potential recommendation of the device to be used for routine breast screenings in non-clinical settings.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day.

-Xenter’s Expanding Team of Industry Leaders Poised to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health-

Merck Announces Effectiveness of the Form 10 Registration Statement for Organon

American Skin Association has announced the recipients of the 2021 David Martin Carter Mentor Award and the 2021 Research Achievement Awards.

Centene Corporation (NYSE: CNC) announced today it will present at the BofA Securities 2021 Healthcare Conference, to be held May 11-13, 2021

Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.

Amphastar Pharmaceuticals, Inc. announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. As part of the restructuring, Amphastar will buyback 26% of ANP’s equity currently held by third parties.